Learn how NICE Advice’s system engagement service helps life sciences companies spot NHS adoption barriers before they become roadblocks.

Around 1,000 people with HER2-low advanced breast cancer can now be offered Enhertu after NICE recommended it for routine NHS use.

People with obsessive-compulsive disorder (OCD) and body dysmorphic disorder (BDD) could be identified earlier and offered more appropriate treatment under draft NICE guidance published today.